China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer ’s disease
Basel, 10 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer ’s disease (AD). This form of AD, known as autosomal dominant AD (ADAD), accounts for less than 1% of all cases of the disease.1 The study, sponsored by Washington University School of Medicine in St. Louis, US, did not show a significant slowing of the rate of cognitive decline in people treated with investigational medicine gantenerumab as measured by the novel DIAN Multivariate Co...
Source: Roche Media News - February 10, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy
Basel, 06 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from the pivotal Part 2 of SUNFISH, a global placebo-controlled study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study showed that change from baseline in the primary endpoint of the Motor Function Measure scale (MFM-32)1 was significantly greater in people treated with risdiplam, compared to placebo (1.55 point mean difference; p=0.0156). The Revised Upper Limb Module (RULM),2 a key secondary endpoint, also showed an improvement (1.59 point difference; p=0.0028). Safety for risdi...
Source: Roche Media News - February 6, 2020 Category: Pharmaceuticals Source Type: news

Roche reports very strong results in 2019
Group sales increase 9% at constant exchange rates and 8% in Swiss francs, driven by new products, more than compensating for impact of competition from biosimilars (Source: Roche Media News)
Source: Roche Media News - January 30, 2020 Category: Pharmaceuticals Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 27, 2020 Category: Pharmaceuticals Source Type: news

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasiv e urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we w...
Source: Roche Media News - January 24, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy
             Basel, 23 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA). The primary outcome measure of the study was the proportion of infants sitting without support for at least five seconds at 12-months of treatment, assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III). Safety for risdiplam in the FIREFISH study was con...
Source: Roche Media News - January 23, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the European Commission has granted conditional marketing authorisation for Polivy ® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - January 21, 2020 Category: Pharmaceuticals Source Type: news

Roche and Illumina partner to broaden patient access to genomic testing
             Basel, 13 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology. As the understanding of the genomic drivers of cancer evolves, NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. This agreement brings together complementary capabilities of each company to broaden global adoption of NGS in cancer care. As pa...
Source: Roche Media News - January 13, 2020 Category: Pharmaceuticals Source Type: news

Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy
Basel, 23 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), today announced the signing of a licensing agreement providing Roche exclusive commercial rights to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin),   Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the United States. Under the terms of the agreement, Sarepta will receive an upfront payment of $750million in cash and $400million in equity. In addition, Sarepta is eligible to receive regulatory and sales m ilestones, and royalties on net sales. Roche and Sarepta will equally s...
Source: Roche Media News - December 23, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
             Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, ...
Source: Roche Media News - December 19, 2019 Category: Pharmaceuticals Source Type: news

Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together...
Source: Roche Media News - December 17, 2019 Category: Pharmaceuticals Source Type: news

Roche purchases shares in tender offer for Spark Therapeutics, Inc.
Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Spark, at a price of USD 114.50 per share in ca sh.  The tender offer expired at 5:00 p.m., New York City time, on 16 December 2019 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of appr...
Source: Roche Media News - December 17, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc
  (Source: Roche Media News)
Source: Roche Media News - December 16, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the Federal Trade Commission closed its investigation and granted unconditional clearance and termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) in connection with Roche’s pending acquisition of Spark p ursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes...
Source: Roche Media News - December 16, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority
Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchas...
Source: Roche Media News - December 16, 2019 Category: Pharmaceuticals Source Type: news

Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - December 13, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche today announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Hercep tin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - December 12, 2019 Category: Pharmaceuticals Source Type: news

APHINITY six-year results strengthen evidence of clinical benefit with Roche ’s Perjeta-based regimen
Roche the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - December 11, 2019 Category: Pharmaceuticals Source Type: news

Roche receives CE Mark for its Accu-Chek SugarView app
Roche today announced that it has obtained the CE Mark for its Accu-Chek SugarView app. (Source: Roche Media News)
Source: Roche Media News - December 10, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any wit hholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the “Offer”). (Source: Roche Media News)
Source: Roche Media News - December 9, 2019 Category: Pharmaceuticals Source Type: news

Changes in the Board of Directors and the Corporate Executive Committee of Roche
Roche announced today that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting on 17 March 2020. (Source: Roche Media News)
Source: Roche Media News - December 9, 2019 Category: Pharmaceuticals Source Type: news

New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data from two pivotal phase III Venclexta ®/Venclyxto® (venetoclax) studies (MURANO and CLL14) that highlight Venclexta/Venclyxto combination treatments as chemotherapy-free, fixed-duration options that achieve minimal residual disease (MRD)-negativity, in people with chronic lymphocytic leukaemia (CLL). (Source: Roche Media News)
Source: Roche Media News - December 8, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - December 4, 2019 Category: Pharmaceuticals Source Type: news

Positive phase III results for Roche ’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine
Roche announced today that data from SAkuraSky, a pivotal phase III study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), were published in the 27 November 2019 online issue of the New England Journal of Medicine (NEJM). (Source: Roche Media News)
Source: Roche Media News - December 2, 2019 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s risdiplam for spinal muscular atrophy
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor neuron-2 (SMN-2) splicing modifier for SMA. (Source: Roche Media News)
Source: Roche Media News - November 25, 2019 Category: Pharmaceuticals Source Type: news

Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer
Roche will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab). The data show statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - November 22, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any wit hholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the “Offer”). (Source: Roche Media News)
Source: Roche Media News - November 22, 2019 Category: Pharmaceuticals Source Type: news

Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium
Roche today announced that results from a number of studies from across its growing breast cancer portfolio will be presented at the San Antonio Breast Cancer Symposium (SABCS), from 10-14 December 2019. (Source: Roche Media News)
Source: Roche Media News - November 18, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Media News)
Source: Roche Media News - November 15, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends conditional EU approval of Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy ® (polatuzumab vedotin) in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - November 15, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone
Roche today announced data from the phase II NOBILITY study, investigating the safety and efficacy of Gazyva ® (obinutuzumab) for adults with proliferative lupus nephritis.1 The study met the primary endpoint with Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrating superiority compared to placebo plus standard of care. (Source: Roche Media News)
Source: Roche Media News - November 11, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy
Roche today announced positive data from the pivotal Part 2 of SUNFISH, a study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). (Source: Roche Media News)
Source: Roche Media News - November 11, 2019 Category: Pharmaceuticals Source Type: news

Roche to present new data highlighting breadth of haematology portfolio and pipeline at the American Society of Hematology 2019 Annual Meeting
Roche today announced new data for its approved and investigational medicines across a range of blood diseases will be presented at the 61st American Society of Hematology (ASH) Annual Meeting from 7 – 10 December, 2019 in Orlando, Florida, US. (Source: Roche Media News)
Source: Roche Media News - November 6, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA
Roche announced today that the European Medicines Agency (EMA) has validated the company ’s Marketing Authorisation Application (MAA) for satralizumab for the treatment of adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD), granting it Accelerated Assessment. Validation confirms that the submission is complete and signifies the MAA is under review by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The U.S. Food and Drug Administration (FDA) has also accepted the company’s Biologics License Application (BLA) for satralizumab. The CHMP recommendation and the F...
Source: Roche Media News - October 30, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any wit hholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the “Offer”). (Source: Roche Media News)
Source: Roche Media News - October 29, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
Roche today announced that the Phase III IMbrave150 study, evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements i n overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. (Source: Roche Media News)
Source: Roche Media News - October 21, 2019 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications
Roche today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications. (Source: Roche Media News)
Source: Roche Media News - October 18, 2019 Category: Pharmaceuticals Source Type: news

Roche reports very strong sales growth in the first nine months of 2019 – outlook raised
Group sales increase 10% at constant exchange rates and 9% in Swiss francs, due to new products Pharmaceuticals Division sales up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta Diagnostics Division sales grow 4%, primarily due to its immunodiagnostic testing portfolio (Source: Roche Media News)
Source: Roche Media News - October 16, 2019 Category: Pharmaceuticals Source Type: news

Phase III PEMPHIX study shows Roche ’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Media News)
Source: Roche Media News - October 14, 2019 Category: Pharmaceuticals Source Type: news

Roche presents positive Phase III results for Tecentriq ® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche today presented positive results from the Phase III IMvigor130 study evaluating Tecentriq ® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line (initial) treatment of people with previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy. (Source: Roche Media News)
Source: Roche Media News - September 30, 2019 Category: Pharmaceuticals Source Type: news

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detect specific fusions with the aim of selecting treatment for people with advanced non-small cell lung cancer (NSCLC), without the need for tissue biopsy. (Source: Roche Media News)
Source: Roche Media News - September 30, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Rituxan (rituximab) in children with two rare blood vessel disorders
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older. (Source: Roche Media News)
Source: Roche Media News - September 30, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any wit hholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the “Offer”). (Source: Roche Media News)
Source: Roche Media News - September 30, 2019 Category: Pharmaceuticals Source Type: news

Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
Roche will present new data at the European Society for Medical Oncology (ESMO) 2019 congress, announcing the results of a number of studies in patients receiving Alecensa ® (alectinib) for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 28, 2019 Category: Pharmaceuticals Source Type: news

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). (Source: Roche Media News)
Source: Roche Media News - September 27, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
Roche will today present results from a Phase Ib study evaluating the efficacy and safety of Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - September 27, 2019 Category: Pharmaceuticals Source Type: news

Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
Roche today announced that results from a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress, taking place from 27 September - 1 October in Barcelona, Spain. (Source: Roche Media News)
Source: Roche Media News - September 23, 2019 Category: Pharmaceuticals Source Type: news

FDA approves cobas Babesia, Roche ’s first whole blood test for donor screening
Roche today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the cobas Babesia test for use on the cobas 6800/8800 Systems for individual blood donation testing. (Source: Roche Media News)
Source: Roche Media News - September 20, 2019 Category: Pharmaceuticals Source Type: news

Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary
Roche today announced its renewed support of the Phelophepa primary healthcare trains in South Africa as the main external sponsor to mark this milestone 25th anniversary. (Source: Roche Media News)
Source: Roche Media News - September 19, 2019 Category: Pharmaceuticals Source Type: news